FI89984B - Enstegsimmuntest foer bestaemning av antigenspecifika antikroppar hoerande till immunoglobulingruppen a, m, d eller e och medel daerfoer - Google Patents
Enstegsimmuntest foer bestaemning av antigenspecifika antikroppar hoerande till immunoglobulingruppen a, m, d eller e och medel daerfoer Download PDFInfo
- Publication number
- FI89984B FI89984B FI882356A FI882356A FI89984B FI 89984 B FI89984 B FI 89984B FI 882356 A FI882356 A FI 882356A FI 882356 A FI882356 A FI 882356A FI 89984 B FI89984 B FI 89984B
- Authority
- FI
- Finland
- Prior art keywords
- antigen
- immunoglobulin
- antibodies
- solid phase
- labeled
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 80
- 102000036639 antigens Human genes 0.000 title claims abstract description 78
- 108091007433 antigens Proteins 0.000 title claims abstract description 78
- 230000007613 environmental effect Effects 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 39
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 39
- 239000007790 solid phase Substances 0.000 claims abstract description 29
- 230000027455 binding Effects 0.000 claims abstract description 18
- 239000012634 fragment Substances 0.000 claims abstract description 16
- 229940027941 immunoglobulin g Drugs 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 53
- 229940072221 immunoglobulins Drugs 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 4
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 4
- 230000000984 immunochemical effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 101710132601 Capsid protein Proteins 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- 241000223997 Toxoplasma gondii Species 0.000 claims description 2
- 241000589884 Treponema pallidum Species 0.000 claims description 2
- 208000005252 hepatitis A Diseases 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000007813 immunodeficiency Effects 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 201000005404 rubella Diseases 0.000 claims description 2
- 239000000700 radioactive tracer Substances 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 abstract description 5
- 239000012530 fluid Substances 0.000 abstract description 3
- 238000001514 detection method Methods 0.000 description 13
- 241000223996 Toxoplasma Species 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- 102000013415 peroxidase activity proteins Human genes 0.000 description 10
- 108040007629 peroxidase activity proteins Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 229940043517 specific immunoglobulins Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 229940098197 human immunoglobulin g Drugs 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000013026 undiluted sample Substances 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (10)
1. Immunokemiskt förfarande för bestämning av anti-genspecifika antikroppar tillhörande immunoglobulinklas- 5 serna A, M, D eller E, i en vätska, varvid en fast fas, vid vilken bundits antikroppar mot denna immunoglobulin-klass eller ett fragment av en sadan antikropp, bringas i kontakt med vätskan, varvid immunoglobulinklassen binds vid den fasta fasen, och den fasta fasen bringas i kontakt 10 antingen med en antigen märkt med ett märkämne, eller med en omärkt antigen och en märkt antikropp eller ett märkt fragment av en antikropp mot antigenen, och pä basen av mängden märkämne som bundits vid den fasta fasen bestäms mängden av de antigenspecifikä antikropparna tillhörande 15 nägon av de nämnda immunoglobulinklasserna, känne-t e c k n a t därav, att den fasta fasen samtidigt är i kontakt med vätskan som innehäller antikropparna som skall bestämmas och med antingen den märkta eller omärkta antigenen, varvid man som ämne som hindrar att immunoglobulin 20 G binds vid den fasta fasen och att antigen eventuellt binds vid immunoglobulin G, tillsätter anti-humant-IgG, aggregerat humant eller animalt IgG eller ett gamma-Fc-fragment.
2. Förfarande enligt patentkravet 1, känne-25 tecknat därav, att man använder märkt antigen.
3. Förfarande enligt patentkravet 1, känne-tecknat därav, att man använder omärkt antigen och en mot denna antigen riktad märkt antikropp eller ett märkt fragment av en sädan antikropp. 30
4. Förfarande enligt patentkravet 1, känne- tecknat därav, att ena eller bäda antikropparna är monoklonala antikroppar eller ett fragment av monoklonala antikroppar.
5. Förfarande enligt patentkravet 1, känne-35 tecknat därav, att antikropparna som skall bestäm- 18 ;;;;·4 mas är antikroppar ur immunoglobulinklassen M, vilka är riktade mot hepatit B-kärnprotein, antigener av hepatit A, human immunbrist-(HIV)-antigener, röda hund- eller cyto-megalovirusantigener eller proteiner av Treponema palla-5 dium eller Toxoplasma gondii.
6. Förfarande enligt patentkravet 1, kanne-t e c k n a t därav, att märkämnet är ett enzym.
7. Förfarande enligt patentkravet 1, k ä n n e -t e c k n a t därav, att märkämnet utgörs av erytrocyter.
8. Medel för att utföra förfarandet enligt patent kravet 1, kännetecknat därav, att det ätmins-tone bestär av en bärare, vid vilken bundits antikroppar som är specifika mot humant IgM, samt märkt antigen mot vilket IgM:t är specifikt, reagens för pävisning eller 15 bestämning av märkningen och ett ämne, som hindrar att immunoglobulin G binds vid den fasta fasen och att antigen eventuellt binds vid immunoglobulin G, och som är anti-humant-IgG, aggregerat humant eller animalt IgG eller ett gamma-Fc-fragment.
9. Medel för att utföra förfarandet enligt patent kravet 1, kännetecknat därav, att det ätmins-tone bestär av en bärare, vid vilken bundits antikroppar som är specifika mot humant IgM, samt antigen, märkta an-tigenspecifikä antikroppar, reagens för pävisning av märk-25 ningen och ett ämne, som hindrar att immunoglobulin G binds vid den fasta fasen och att antigen eventuellt binds vid immunoglobulin G och som är anti-humant-IgG, aggregerat humant eller animalt IgG eller ett gamma-Fc-fragment.
10. Medel för att utföra förfarandet enligt patent-30 kravet 1, kännetecknat därav, att det bestär av ett enda element, vilket innehäller alla för förfarandet erfoderliga reagens i torkad form.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3717401 | 1987-05-23 | ||
| DE19873717401 DE3717401A1 (de) | 1987-05-23 | 1987-05-23 | Einschritt-immuntest zur bestimmung von antigen-spezifischen antikoerpern aus einer der immunglobulin-klassen a, m, d oder e und dazu geeignetes mittel |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI882356A0 FI882356A0 (fi) | 1988-05-19 |
| FI882356A FI882356A (fi) | 1988-11-24 |
| FI89984B true FI89984B (fi) | 1993-08-31 |
| FI89984C FI89984C (sv) | 1993-12-10 |
Family
ID=6328247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI882356A FI89984C (sv) | 1987-05-23 | 1988-05-19 | Enstegsimmuntest för bestämning av antigenspecifika antikroppar hörand e till immunoglobulingruppen A, M, D eller E och medel därför |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6632682B1 (sv) |
| EP (1) | EP0292810B1 (sv) |
| JP (1) | JP2636331B2 (sv) |
| AT (1) | ATE93060T1 (sv) |
| AU (1) | AU619183B2 (sv) |
| CA (1) | CA1336063C (sv) |
| DE (2) | DE3717401A1 (sv) |
| DK (1) | DK173687B1 (sv) |
| ES (1) | ES2059434T3 (sv) |
| FI (1) | FI89984C (sv) |
| NO (1) | NO172264C (sv) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3837616A1 (de) * | 1988-11-05 | 1990-05-10 | Behringwerke Ag | Einschritt-immuntest zur bestimmung von antigen-spezifischen antikoerpern aller immunglobulin-klassen und dazu geeignetes mittel |
| FR2640143B1 (fr) * | 1988-12-13 | 1991-03-15 | Maes Ludo | Anticorps polymerises, diriges contre des immunoglobulines - leur utilisation dans des tests de diagnostic |
| JPH0325366A (ja) * | 1989-06-22 | 1991-02-04 | Dai Ichi Pure Chem Co Ltd | 特異抗体の測定法 |
| WO1991008485A1 (en) * | 1989-12-01 | 1991-06-13 | Pb Diagnostic Systems, Inc. | Immunoassay for antibodies to infectious disease agents |
| DE4040306A1 (de) * | 1990-12-17 | 1992-06-25 | Behringwerke Ag | Verfahren zur bestimmung von antikoerpern gegen lipocortine |
| WO1992018865A1 (en) * | 1991-04-11 | 1992-10-29 | Cedars-Sinai Medical Center | Immunoassay for the detection of hiv specific igm |
| DE4439452A1 (de) * | 1994-11-04 | 1996-05-09 | Boehringer Mannheim Gmbh | Antikörperklassenspezifisches Entstörungsreagenz |
| DE19649389A1 (de) * | 1996-11-29 | 1998-06-04 | Boehringer Mannheim Gmbh | Antigenspezifischer IgM-Nachweis |
| DE69931632T2 (de) * | 1998-03-30 | 2006-12-07 | Orasure Technologies, Inc. | Sammelapparat für einschrittigen test von mundflüssigkeiten |
| US6303081B1 (en) * | 1998-03-30 | 2001-10-16 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
| US8062908B2 (en) * | 1999-03-29 | 2011-11-22 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
| HU228049B1 (en) * | 1998-06-24 | 2012-09-28 | Alk Abello As | Method of detecting an antibody in a liquid sample |
| US8323903B2 (en) | 2001-10-12 | 2012-12-04 | Life Technologies Corporation | Antibody complexes and methods for immunolabeling |
| US20050069962A1 (en) | 2001-10-12 | 2005-03-31 | Archer Robert M | Antibody complexes and methods for immunolabeling |
| EP2184608B1 (en) * | 2007-08-23 | 2016-10-05 | LSI Medience Corporation | Non-specific reaction inhibitor |
| KR101343035B1 (ko) * | 2008-12-22 | 2013-12-18 | 삼성전자 주식회사 | 제1수용체, 차단물질 및 제2수용체가 고정화된 고체 기판을포함하는 표적물질을 분석하기 위한 물품 및 그 용도 |
| WO2011074965A1 (en) * | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Methods and means for counteracting an activity of an fc domain |
| US10260111B1 (en) | 2014-01-20 | 2019-04-16 | Brett Eric Etchebarne | Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample |
| WO2020061135A1 (en) * | 2018-09-18 | 2020-03-26 | Siemens Healthcare Diagnostics Inc. | Methods and reagents for zika virus immunoassays |
| FR3110245A1 (fr) * | 2019-05-16 | 2021-11-19 | Universite Jean Monnet Saint Etienne | Procede de detection de pneumocoques |
| CN111077323A (zh) * | 2020-01-12 | 2020-04-28 | 天津市宝坻区人民医院 | 消除胰岛素自身抗体干扰的胰岛素测定试剂盒 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4130634A (en) * | 1974-03-15 | 1978-12-19 | University Of Illinois Foundation | Method for detecting and quantifying antigens |
| DE2643208C2 (de) * | 1976-09-25 | 1985-09-05 | Behringwerke Ag, 3550 Marburg | Immunologisches Bestimmungsverfahren |
| US4273756A (en) * | 1978-07-28 | 1981-06-16 | Abbott Laboratories | Immunoassay for class specific antibodies |
| US4292403A (en) * | 1978-08-24 | 1981-09-29 | Akzona Incorporated | Detection and/or determination of IgM, IgA, IgD and IgE immunoglobulins |
| EP0008473B1 (en) * | 1978-08-24 | 1983-06-01 | Akzo N.V. | Method for the detection and/or determination of an antigen specific immunoglobulin, immuno-reagents to be used in said method and test kit for said determination |
| DE2930706A1 (de) * | 1979-07-28 | 1981-02-05 | Medac Klinische Spezialpraep | Verfahren zum nachweis von erregerspezifischen antikoerpern |
| US4486530A (en) * | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| DE3111474A1 (de) | 1981-03-24 | 1982-10-07 | Behringwerke Ag, 3550 Marburg | "mittel zur immunologischen diagnose sowie verfahren zu seiner herstellung" |
| DE3266967D1 (en) * | 1982-01-05 | 1985-11-21 | Int Inst Cellular Molecul Path | Method of immunoassay |
| US4434227A (en) * | 1982-02-08 | 1984-02-28 | Abbott Laboratories | Immunoassay for class specific immunoglobulin antibodies |
| DE3206729A1 (de) * | 1982-02-25 | 1983-09-01 | Behringwerke Ag, 3550 Marburg | Immunologisches agglutinationsverfahren |
| US4477576A (en) * | 1982-07-26 | 1984-10-16 | Mex Research Associates | Antigen assay method and kit |
| FR2534030A1 (fr) * | 1982-10-01 | 1984-04-06 | Pasteur Institut | Procede de detection et de dosage d'une substance biologique par erythroadsorption |
| US4663277A (en) * | 1983-05-20 | 1987-05-05 | Profile Diagnostic Sciences Inc. | Virus detection method and materials |
| JPS60256057A (ja) * | 1984-06-01 | 1985-12-17 | Dai Ichi Pure Chem Co Ltd | 免疫学的測定法 |
| JPS61942A (ja) * | 1984-06-14 | 1986-01-06 | Matsushita Electric Ind Co Ltd | 光情報記録媒体 |
| DE3662730D1 (en) * | 1985-01-24 | 1989-05-11 | Inst Int Pathologie Cellulaire | Immunoassay method for antibodies of different classes in a liquid sample |
| BE901567A (fr) * | 1985-01-24 | 1985-05-17 | Inst Internat De Pathologie Ce | Procede de dosage immunologique d'anticorps de diverses classes dans un echantillon liquide. |
| IL80129A0 (en) * | 1986-09-23 | 1986-12-31 | Savyon Diagnostics Ltd | Method for the determination of igm and iga immunoglobulins and reagents therefor |
| US4962023A (en) * | 1987-06-22 | 1990-10-09 | Louisiana State University, Agricultural And Mechanical College | Single incubation immuno sorbent assay method using particle labels to detect test antigen specific antibodies in presence of other antibodies |
-
1987
- 1987-05-23 DE DE19873717401 patent/DE3717401A1/de not_active Withdrawn
-
1988
- 1988-05-13 EP EP88107704A patent/EP0292810B1/de not_active Expired - Lifetime
- 1988-05-13 AT AT88107704T patent/ATE93060T1/de not_active IP Right Cessation
- 1988-05-13 DE DE8888107704T patent/DE3883073D1/de not_active Expired - Fee Related
- 1988-05-13 ES ES88107704T patent/ES2059434T3/es not_active Expired - Lifetime
- 1988-05-19 FI FI882356A patent/FI89984C/sv not_active IP Right Cessation
- 1988-05-20 CA CA000567380A patent/CA1336063C/en not_active Expired - Fee Related
- 1988-05-20 JP JP63122214A patent/JP2636331B2/ja not_active Expired - Fee Related
- 1988-05-20 DK DK198802775A patent/DK173687B1/da not_active IP Right Cessation
- 1988-05-20 NO NO882204A patent/NO172264C/no unknown
- 1988-05-20 AU AU16485/88A patent/AU619183B2/en not_active Ceased
-
1995
- 1995-05-22 US US08/445,584 patent/US6632682B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU619183B2 (en) | 1992-01-23 |
| JP2636331B2 (ja) | 1997-07-30 |
| DE3883073D1 (de) | 1993-09-16 |
| NO882204D0 (no) | 1988-05-20 |
| FI882356A0 (fi) | 1988-05-19 |
| FI882356A (fi) | 1988-11-24 |
| EP0292810A2 (de) | 1988-11-30 |
| US6632682B1 (en) | 2003-10-14 |
| NO172264C (no) | 1993-06-23 |
| ATE93060T1 (de) | 1993-08-15 |
| DK277588D0 (da) | 1988-05-20 |
| ES2059434T3 (es) | 1994-11-16 |
| CA1336063C (en) | 1995-06-27 |
| NO172264B (no) | 1993-03-15 |
| EP0292810B1 (de) | 1993-08-11 |
| FI89984C (sv) | 1993-12-10 |
| AU1648588A (en) | 1989-11-23 |
| DK277588A (da) | 1988-11-24 |
| DK173687B1 (da) | 2001-06-25 |
| DE3717401A1 (de) | 1988-12-08 |
| JPH01118769A (ja) | 1989-05-11 |
| NO882204L (no) | 1988-11-24 |
| EP0292810A3 (en) | 1989-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI89984B (fi) | Enstegsimmuntest foer bestaemning av antigenspecifika antikroppar hoerande till immunoglobulingruppen a, m, d eller e och medel daerfoer | |
| CA1111346A (en) | Assay of antibodies of double surface reagent in presence of interfering materials | |
| Yolken | Enzyme-linked immunosorbent assay (ELISA): a practical tool for rapid diagnosis of viruses and other infectious agents. | |
| US4292403A (en) | Detection and/or determination of IgM, IgA, IgD and IgE immunoglobulins | |
| US6489129B1 (en) | Antigen-specific IgM detection | |
| JP3330604B2 (ja) | 固相免疫学的検定法 | |
| JP2599058B2 (ja) | クラス特異的な免疫グロブリン抗体の免疫分析法 | |
| JPS6367661B2 (sv) | ||
| GB2026691A (en) | Determination of class-specific antibody | |
| KR20000057316A (ko) | 항원-특이적 면역글로불린 지 검출방법 | |
| US6143510A (en) | Measuring method using whole blood sample | |
| US20020187510A1 (en) | Method for assay of antibodies and antibody assay device | |
| JPH0346561A (ja) | 分析物検出のための方法、試薬及び試験ストリップ | |
| AU619019B2 (en) | An article for performing immunological assays utilizing organic dyes and methods for producing and utilizing same | |
| CA2008100A1 (en) | Method for the determination of immunologically detectable substance | |
| KR920005964B1 (ko) | 항원에 대해 특이적인 종류의 항체 측정 방법 및 이 방법을 실행하기 위한 시약 | |
| CA1334825C (en) | Solid phase indicator red blood cells and method | |
| JPH01209370A (ja) | 免疫活性物質の測定法及び測定試薬 | |
| JPH0421819B2 (sv) | ||
| EP0304238A2 (en) | Method for detecting and confirming the presence of antibodies | |
| EP0762123A1 (en) | Immunoassay device and immunoassay method using the same | |
| JP2972241B2 (ja) | 全イムノグロブリンクラスの抗原特異的抗体を測定するための１段階イムノアツセイ | |
| JPH10319017A (ja) | 蛍光エネルギー転移を利用した物質の測定方法およびそのための試薬 | |
| AU645970B2 (en) | A method for the determination of antibodies against organisms causing infectious diseases in body fluids, agents for this purpose and the use thereof in this method | |
| CA2172840C (en) | Measuring method using whole blood sample |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| PC | Transfer of assignment of patent |
Owner name: DADE BEHRING MARBURG GMBH |
|
| FG | Patent granted |
Owner name: DADE BEHRING MARBURG GMBH |
|
| MA | Patent expired |